A centre-based chart review study to assess treatment outcomes of venetoclax for the treatment of acute myeloid leukemia (AML)

AbbVie (United Kingdom)0 个研究点目标入组 168 人开始时间: 2023年11月10日最近更新: 2024年9月2日

适应症

试验速览

暂无简介。

•1. The patient received a diagnosis for AML, if available, suggested diagnosis codes: ICD-9 205.0x or ICD-10 C92.0x, C92.4x, C92.5x
•2. The patient was at least 18 years old at AML diagnosis date
•3. The patient was initiated on the studied line of therapy (see Table 1 for the list of eligible treatments included based on NCCN guidelines and clinical input) for previously untreated AML:
•3.1. Venetoclax in combination with an HMA (on or after 28th May 2021) or LDAC (on or after 25th February 2022), the date of MHRA approvals of venetoclax (for the treatment of adult patients with newly diagnosed AML who are ineligible for intensive chemotherapy)
•4. The patient was treated with the studied line of therapy at least 28 days prior to the date of data collection
•5. Information on the patient's treatments, selected (or important) clinical characteristics, and outcomes is available from the start of the studied line of therapy onwards

•1. The patient received the studied line of therapy as part of a clinical trial
•2. The patient received prior lines of therapy for AML
•3. The patient has a history of malignancies within 2 years prior to the studied line of therapy, other than AML, and with the exception of:
•3.1. Myelodysplastic syndromes (MDS), myeloproliferative neoplasm (MPN) or chronic myelomonocytic leukemia (CMML)
•3.2. Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of the breast
•3.3. Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin
•3.4. Previous malignancy confined and surgically resected (or treated with other
•modalities) with curative intent

发起方

AbbVie (United Kingdom)